AP
Amcor plc (AMCR)·Q1 2026 Earnings Summary
Executive Summary
- Q1 2026 delivered solid integration-driven results: net sales $5.745B, adjusted EBIT $687M, adjusted EPS $0.193; reaffirmed FY26 guidance for adjusted EPS $0.80–$0.83 and FCF $1.8–$1.9B .
- EPS beat consensus (0.193 vs 0.184), while revenue was slightly below (actual $5.745B vs $5.761B); beat driven by $38M synergies, disciplined cost and productivity; revenue softness tied to ~2% lower combined volumes and unfavorable price/mix in certain categories .
- Margins expanded: adjusted EBIT margin 12.0% (+110 bps YoY), with both Flexible and Rigid segments improving; Rigid margin +420 bps YoY reflecting quality of combined business .
- Dividend raised to $0.13; management reiterated confidence in at least $260M FY26 synergies and $650M through FY28; portfolio optimization progressing (two small asset sale agreements, NA beverage designated non-core) .
- Catalysts: guidance reaffirmation, visible synergy momentum, margin expansion across segments, and increased dividend support a positive narrative despite volume headwinds .
What Went Well and What Went Wrong
What Went Well
- Synergies at upper end of range: ~$38M in Q1 (≈$33M to EBIT and ~$5M to interest), underpinning EPS beat and margin expansion .
- Segment margin gains: Flexible adjusted EBIT margin 13.1% (+20 bps YoY) and Rigid 11.9% (+420 bps YoY), reflecting improved cost performance and acquisition benefits .
- Confident outlook reaffirmed: FY26 adjusted EPS $0.80–$0.83 and FCF $1.8–$1.9B; capex $850–$900M, net interest $570–$600M, ETR 19–21% .
- Management quote: “Adjusted EPS of 19.3 cents per share was above the mid-point of our guidance... supported by disciplined cost performance, improved productivity and delivery of synergies...” — CEO Peter Konieczny .
What Went Wrong
- Volumes: combined Q1 volumes ~2% below prior year (ex. non-core NA beverage); Flexible volumes down ~2.8% and Rigid down ~1% (ex. NA beverage) .
- Price/mix headwinds: Rigid experienced unfavorable price/mix and pass-through of lower raw materials (~-6%), weighing on net sales despite acquired growth .
- NA beverage still a drag: volumes high-single-digit declines last quarter and operational issues persisted into Q4 FY25, with elevated costs expected in Q1; strategic alternatives remain under evaluation .
Financial Results
Quarter-over-Quarter
Year-over-Year (Q1)
Versus Wall Street Estimates (Q1 2026)
Values with asterisk retrieved from S&P Global.
Segment Breakdown (Q1 2026)
KPIs (Q1 2026)
Drivers: acquired sales ($2.4B net of divestments), synergies ($33M to EBIT), disciplined cost, improved productivity; headwinds included lower volumes and unfavorable price/mix in Rigid .
Guidance Changes
Management also noted FY26 phasing: H2 weighted (≈55% of EPS in H2), with synergy run-rate building through the year .
Earnings Call Themes & Trends
Management Commentary
- “We have clear line of sight to delivering at least $260 million of synergy benefits in fiscal 26, and... $650 million... by fiscal 28; synergies alone to drive more than 30% EPS growth” — CEO Peter Konieczny .
- “Adjusted EPS of $0.193 per share was above the midpoint... supported by disciplined cost performance, improved productivity and delivery of synergies...” — CEO Peter Konieczny .
- “Leverage exiting the quarter was 3.6x... on track to reach 3.1–3.2x by fiscal year-end” — CFO Michael Casamento .
- “We increased our quarterly dividend... $0.13 per share... reaffirmed FY26 EPS and FCF guidance” — CEO Peter Konieczny .
Q&A Highlights
- Flexibles demand softness centered in Europe’s unconverted film; overall Q1 volumes down ~2% ex non-core NA beverage, as expected .
- NA beverage: operational issues addressed and “under control”; sequential profitability improved; strategic alternatives (JV/partnerships) progressing .
- Synergies detail: $38M in Q1, ~$33M EBIT and ~$5M interest; ~2/3 G&A and ~1/3 procurement; run-rate to build through Q2/Q3 .
- Focus categories outperformed (petcare, dairy); beauty & wellness down low-single digits; healthcare flat overall with strength in NA medical .
- Private label: underrepresented; targeted growth to participate in value-seeking consumer trend .
Estimates Context
- Q1 2026 EPS beat: actual 0.193 vs consensus 0.184; revenue slight miss: actual $5.745B vs consensus $5.761B; 11 estimates for each metric*.
- Implications: modest upward bias to FY26 EPS models given synergy momentum and margin expansion; revenue trajectories likely tempered by continued volume headwinds and price/mix pressure in Rigid*.
Values retrieved from S&P Global.
Key Takeaways for Investors
- Integration synergy cadence is tracking ahead, driving EPS beats and multi-segment margin expansion; maintain overweight on synergy realization into H2 .
- Reaffirmed FY26 EPS and FCF guidance, with results not reliant on macro improvement; risk-adjusted confidence rooted in controllable self-help .
- NA beverage is ring-fenced as non-core and operational issues are stabilizing; potential strategic action could unlock value and aid deleveraging .
- Flexible/rigid portfolio shows resilience in focus categories (petcare, dairy, healthcare) amid consumer value-seeking; position for mix benefits .
- Dividend increase signals cash flow confidence; leverage path toward ~3.1–3.2x by FY-end supports capital return optionality .
- Near-term trading: expect narrative support from synergy updates and segment margin prints; monitor EU flexibles film and rigid price/mix headwinds .
- Medium-term thesis: $650M synergies by FY28, portfolio optimization, and cross-selling across expanded formats/materials underpin >30% EPS growth from synergies alone .